Video Experimental Relacionado
Updated: Jul 15, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Prazosin-nuevo agente hipertensivo. Un estudio cruzado doble ciego en el tratamiento de la hipertensión
JAMA
|March 7, 1977
Resumen
El clorhidrato de prazosina mostró un efecto antihipertensivo menor que el de la hidroclorotiazida en pacientes con hipertensión leve a moderada. La prazosina puede ser más efectiva como tratamiento secundario o terciario en la terapia de combinación.
Área de la Ciencia:
- Medicina cardiovascular La medicina cardiovascular es una especialidad de la medicina cardiovascular.
- Farmacología Farmacología.
Sus antecedentes:
- El clorhidrato de prazosina es un agente antihipertensivo.
- Su potencia se considera de leve a moderada como agente único para la hipertensión leve a moderada o en combinación para la hipertensión severa.
Objetivo del estudio:
- Para comparar los efectos antihipertensivos del clorhidrato de prazosina y la hidroclorotiazida.
- Determinar la aplicación óptima de la prazosina en el tratamiento de la hipertensión.
Principales métodos:
- Se realizó un estudio en el que participaron 14 pacientes.
- Se comparó la hidroclorotiazida con el clorhidrato de prazosina.
Principales resultados:
- Se encontró que el efecto antihipertensivo del clorhidrato de prazosina era menos potente que el de la hidroclorotiazida.
- La eficacia de la prazosina fue menor que la de la hidroclorotiazida en esta cohorte de pacientes.
Conclusiones:
- El clorhidrato de prazosina puede no ser tan eficaz como la hidroclorotiazida como agente primario.
- El uso óptimo de la prazosina podría ser como terapia adicional, combinada con diuréticos tiazídicos o agentes bloqueadores beta-adrenérgicos, como tratamiento de segunda o tercera línea para la hipertensión.
Videos de Conceptos Relacionados
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...